arrow
C

Christina Poh

city of hope national medical center
H指数:12
被引数:553

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

塔fasitamab、lenalidomide和阿利霉素在复发或难治性滤泡性淋巴瘤(inMIND)中的研究:一项全球性、III期、随机对照试验

2025-12-050
PRE
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis

Blinatumomab/Lenalidomide治疗复发/难治性B细胞淋巴瘤的I期研究;毒性、疗效及相关性分析

2025-11-120
OAAI
Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia

免疫表型对T细胞原淋巴细胞白血病临床疾病特征和预后的影响

2025-09-010
PRE
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas

普利尔替克酸对细胞毒性皮肤T细胞淋巴瘤有效。

2025-06-190
OA
Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Tafasitamab 联合 Lenalidomide 和 Rituximab 治疗复发或难治性滤泡性淋巴瘤:来自一项 3 期研究(inMIND)的结果

BLOOD
IF23.1
2024-11-253
PRE
Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab plus AVD in Untreated Classic Hodgkin Lymphoma

尽管在接受Pembrolizumab联合AVD治疗的未经治疗经典型霍奇金淋巴瘤患者中频繁出现4级中性粒细胞减少,但发热性中性粒细胞减少的发生率较低。

BLOOD
IF23.1
2024-11-050
PRE
Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL- the Avenue-2 Trial

Acalabrutinib和Venetoclax(AV)联合治疗经治CLL/SLL患者2年——Avenue-2试验

BLOOD
IF23.1
2024-11-050
PRE
Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Pralatrexate 对细胞毒性皮肤T细胞淋巴瘤有效

BLOOD
IF23.1
2024-11-050
PRE
Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab plus AVD for Classic Hodgkin Lymphoma

经典霍奇金淋巴瘤患者接受一线帕博利珠单抗联合AVD治疗时潜在的延迟性免疫相关性不良事件

BLOOD
IF23.1
2024-11-050
PRE
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

Polatuzumab vedotin联合输注入化疗治疗未经治疗的侵袭性b细胞非霍奇金淋巴瘤

2023-05-305
OAAI